TY - JOUR T1 - Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 363 LP - 367 DO - 10.1136/sextrans-2016-052699 VL - 93 IS - 5 AU - Thijs Reyniers AU - Elske Hoornenborg AU - Bea Vuylsteke AU - Kristien Wouters AU - Marie Laga Y1 - 2017/08/01 UR - http://sti.bmj.com/content/93/5/363.abstract N2 - In many Western countries with good coverage of antiretroviral treatment (ART) programmes the annual number of HIV infections is still high and not (yet) declining among men who have sex with men (MSM). This might indicate that antiretroviral treatment roll-out alone will not turn around the course of the epidemic and that new, additional tools are needed. Antiretrovirals used as prevention tools for people not yet infected with HIV, such as pre-exposure prophylaxis (PrEP) could be such important additional tools. PrEP is a new type of biomedical prevention, which involves the use of antiretrovirals before, during and after (periods of) sexual exposure to HIV. In this review, we will focus on PrEP as a new prevention tool for MSM at high risk in Europe, including its evidence for effectiveness, challenges for implementation, ongoing European demonstration studies; as well as how PrEP relates to other existing prevention tools. In light of European Medicines Agency's recent recommendation for approval of PrEP we briefly review the potential implications. ER -